TAVR Performance Requirements: How many, how well, or both?

David M. Shahian, MD Professor of Surgery, Harvard Medical School Chair, STS Council on Quality, Research, and Patient Safety July 25, 2018

Disclosures

No financial disclosures or COI STS: No disclosures



Performance measurement

- STS has been a leader in advocating direct measures of quality and public reporting
- STS has 35 NQF-endorsed quality metrics, most of which are risk-adjusted outcomes
- We prefer outcomes over structure or process measures, although we have used all three



STS Public Reporting Online



dult Cardiac	Congenital Heart	General Thoracic	Resources	Conta	t				
Search AVR Data by Hospital									
Hospital		State							
Filter by name		- Any -	Apply						
Name				¢ Co	overall mposite	Absence of Operative Mortality 🖨	Absence of Major Morbidity		
<u>St. Joseph Med</u> Tacoma, Washi					$\star \star$	★★	\bigstar		
<u>El Camino Hos</u> Mountain View				\bigstar	$\star \star$	**	$\star \star \star$		
Kaiser Sunnyside Medical Center									

MedStar Heart Institute MedStar Washington Hospital Center Washington, District of Columbia

Clackamas, Oregon

CABG Results							
Year	Overall Composite Score*	Absence of Operative Mortality	Absence of Major Morbidity	Use of Internal Mammary Artery	Receipt of Required Perioperative Medications		
July 2015 - June 2016	★ ★ 97.7	★ ★ 97.7	★ ★ 91.1	★ ★ 99.5	$\bigstar \bigstar \bigstar \bigstar _{99.5} \bigstar$		
July 2016 - June 2017	★ ★ 97.7	★ ★ 97.6	92.2	★ ★ 99.5	★ ★ ★ 99.2		
AVR Results							
Year	Overall	Overall Composite Score**		ative Mortality	Absence of Major Morbidity		
July 2014 - June 2017	★ ★ ★		★ · 98.		★ ★ 92.1		
AVR + CABG Results	i						
Year	Overall	Overall Composite Score***		rative Mortality	Absence of Major Morbidity		
July 2014 - June 2017		33.2		*	★★		

Table 3a : TAVR Program Performance Requirements:					
Minimum quality benchmarks for TAVR sites					
2018 Criteria					
Primary Outcome Metrics	Performance Measure				
In-hospital risk-adjusted all-cause mortality	Based on 95% CI and national benchmark data, program's performance "as expected" or "better than expected"				
30-day risk-adjusted all-cause mortality	Based on 95% CI and national benchmark data, program's performance "as expected" or "better than expected"				
30-day all-cause neurologic events including TIAs	Funnel plots: performance within 95% upper control limits (outlier); programs exceeding 90% upper control limits (warning) merit further internal study *				
30-day major vascular complication	Funnel plots: performance within 95% upper control limits (outlier); programs exceeding 90% upper control limits (warning) merit further internal study *				
30-day major bleeding	Funnel plots: performance within 95% upper control limits (outlier); programs exceeding 90% upper control limits (warning) merit further internal study *				
30-day moderate or severe AR	Funnel plots: performance within 95% upper control limits (outlier); programs exceeding 90% upper control limits (warning) merit further internal study *				
Primary Outcome Metrics In Development					
1-year risk-adjusted all-cause mortality					
*Risk-adjusted measures for all major complications (transition to statistical hypothesis testing)					
Patient reported health status (KCCQ) at 30 days and 1 year versus baseline					
30-day and 1-year risk-adjusted mortality and morbidity composite measure					

Why volume thresholds for TAVR?

Expertise: the volume-outcome association


- Volume during procedural adoption--learning curve
- Volume of established procedures--generally correlates with outcomes for complex procedures
- Measurement challenges with low volumes
 - Randomness—inherent uncertainty of small sample estimates
 - Measure reliability



• Statistical power to detect outliers


95% Confidence Intervals

Given a sample of size *n* and its estimate (e.g., 3%), how certain can we be about the true population proportion?




Prediction Intervals (used for funnel plots)


Given known population parameters (mean, distribution), what can we say about estimates from future samples of size *n*?



Spiegelhalter. Statist. Med. 2005; 24:1185–1202



Two statistical tools, same message Estimates from small samples have substantial random variation



Measure reliability (signal to noise ratio) highly dependent on sample size




FIGURE 1. Hospital-level reliability estimates by colectomy annual caseloads based on American College of Surgeons National Surgical Quality Improvement Program-sampled cases in 2010 for the mortality or any serious morbidity composite outcome measure. (Event rate 20%)

Merkow et al Ann Surg 2013;257: 483–489

Statistical Power Decreases with Smaller Sample Size Type II errors more likely

	National postoperative mortality (%)	Median annual number*	Number of procedures necessary to detect poor performance		tect
			60% power	70% power	80% power
Hip fracture surgery	8.4%†	31	56	75	102
Oesophagectomy or gastrectomy	6.1%‡	11	79	109	148
Bowel cancer resection	5.1%§	9	95	132	179
Cardiac surgery	2·7%¶	128	192	256	352


5% significance level. Poor performance defined as double the national overall mortality rate. *On the basis of hospital episode statistics⁵ for the 3-year period from April, 2009, to March, 2012 (except for cardiac surgery, for which reported numbers² are used). †30-day mortality (March 1, 2010–Feb 28, 2011).⁶ ‡90-day mortality (Oct 1, 2007–June 30, 2009).⁷ §90-day mortality (Aug 1, 2010–July 31, 2011).⁸ ¶In-hospital mortality (April 1, 2008–March 31, 2011).⁹

Table 1: Mortality after four surgical procedures, the number of procedures that occur annually, and how many would be necessary to detect poor performance with different statistical powers

TAVR Quality: How many, how well, or both?

- Outcome measure statistics are problematic with small sample sizes (low volume)
- Adequate volume is associated with expertise <u>and</u> facilitates accurate, reliable outcome measurement







AMERICAN COLLEGE of CARDIOLOGY



